## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE TECHNOLOGY APPRAISAL PROGRAMME

## Equality impact assessment - Scoping

## STA Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion

## Batch 26

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No equality issues were identified during the draft scope consultation or scoping workshop discussion.	
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
N/A	
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
N/A	
4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of aflibercept treating visual impairment caused by macular oedema secondary to central retinal vein occlusion

Issue date: June 2013

Approved by Associate Director (name): Frances Sutcliffe

Date: 13 06 2013

Equality impact assessment for the proposed Single Technology Appraisal of aflibercept treating visual impairment caused by macular oedema secondary to central retinal vein occlusion

Issue date: June 2013 2 of 2